ZALTRAP®, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI),
is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is
resistant to or has progressed following an oxaliplatin-containing regimen.
As shown in preclinical studies*...
ZALTRAP® (ziv-aflibercept)
Trapping Multiple Angiogenic Factors1-3
*The clinical significance is unknown.
VEGF-A=vascular endothelial growth factor A.
VEGF-B=vascular endothelial growth factor B.
PlGF=placental growth factor.

ZALTRAP®, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.